Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caitlin B Conboy

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Hepatobiliary Surgery and Nutrition|April 25, 2022
Drivers and breaks in the cholangiocarcinoma immune microenvironmentCaitlin B Conboy, Sumera I Ilyas, Gregory J Gores
JHEP Reports : Innovation in Hepatology|February 11, 2020
Immunobiology of cholangiocarcinomaEmilien Loeuillard, Caitlin B Conboy, Gregory J Gores, et al.
American Journal of Hematology|February 9, 2018
Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A second experienceInuk Zandvakili, Caitlin B Conboy, Ayed O Ayed, et al.
Hepatology (Baltimore, Md.)|November 11, 2024
Hepatology HighlightsRyan Watkins, Sumera I Ilyas, Daniel D Penrice, et al.
Hepatology (Baltimore, Md.)|December 2, 2024
Hepatology highlightsCaitlin B Conboy, Daniel D Penrice, Ryan Watkins, et al.
Molecular Cancer Research : MCR|July 11, 2020
The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in CholangiocarcinomaEeeLN H Buckarma, Nathan W Werneburg, Caitlin B Conboy, et al.
DNA and Cell Biology|December 15, 2020
R-Spondins 2 and 3 Are Overexpressed in a Subset of Human Colon and Breast CancersCaitlin B Conboy, Germán L Vélez-Reyes, Susan K Rathe, et al.
Future Oncology (London, England)|July 28, 2025
A Phase 1 study of the novel GCN2 kinase activator NXP800 in patients with advanced cholangiocarcinomaHendrien Kuipers, Joseph J Larson, Caitlin B Conboy, et al.
Annals of Surgical Oncology|August 14, 2025
Real-World Single-Center Experience with Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab in Borderline Resectable CholangiocarcinomaYawen Dong, Vanja Podrascanin, Zhihao Li, et al.
Annals of Surgical Oncology|August 28, 2025
ASO Visual Abstract: Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel in Borderline Resectable CCA: A Real-World Exploratory AnalysisYawen Dong, Jonas Santol, Vanja Podrascanin, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Hepatobiliary Surgery and Nutrition|April 25, 2022
Drivers and breaks in the cholangiocarcinoma immune microenvironmentCaitlin B Conboy, Sumera I Ilyas, Gregory J Gores
JHEP Reports : Innovation in Hepatology|February 11, 2020
Immunobiology of cholangiocarcinomaEmilien Loeuillard, Caitlin B Conboy, Gregory J Gores, et al.
American Journal of Hematology|February 9, 2018
Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A second experienceInuk Zandvakili, Caitlin B Conboy, Ayed O Ayed, et al.
Hepatology (Baltimore, Md.)|November 11, 2024
Hepatology HighlightsRyan Watkins, Sumera I Ilyas, Daniel D Penrice, et al.
Hepatology (Baltimore, Md.)|December 2, 2024
Hepatology highlightsCaitlin B Conboy, Daniel D Penrice, Ryan Watkins, et al.
Molecular Cancer Research : MCR|July 11, 2020
The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in CholangiocarcinomaEeeLN H Buckarma, Nathan W Werneburg, Caitlin B Conboy, et al.
DNA and Cell Biology|December 15, 2020
R-Spondins 2 and 3 Are Overexpressed in a Subset of Human Colon and Breast CancersCaitlin B Conboy, Germán L Vélez-Reyes, Susan K Rathe, et al.
Future Oncology (London, England)|July 28, 2025
A Phase 1 study of the novel GCN2 kinase activator NXP800 in patients with advanced cholangiocarcinomaHendrien Kuipers, Joseph J Larson, Caitlin B Conboy, et al.
Annals of Surgical Oncology|August 14, 2025
Real-World Single-Center Experience with Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab in Borderline Resectable CholangiocarcinomaYawen Dong, Vanja Podrascanin, Zhihao Li, et al.
Annals of Surgical Oncology|August 28, 2025
ASO Visual Abstract: Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel in Borderline Resectable CCA: A Real-World Exploratory AnalysisYawen Dong, Jonas Santol, Vanja Podrascanin, et al.
Pageof 3